A Phase 3 interventional study of fordadistrogene movaparvovec in Duchenne Muscular Dystrophy, sponsored by Pfizer. Terminated at 12 sites in United States. Open to male participants aged 0 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Pfizer · Phase 3, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 233 studies in Muscular Dystrophy, Duchenne with a site in United States — 35 open to participants now, 60 under way, 8 of them phase 3. Muscular Dystrophy, Duchenne · United States.
Among the 233 studies in Muscular Dystrophy, Duchenne with a site in United States, this one is the 144th largest by enrollment of the 172 interventional ones that give a count, is one of 6 that started in 2023, is one of 32 in phase 3, and was the 191st registered.
482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.
Browse Muscular Dystrophy, Duchenne studies →35 of the 233 studies in Muscular Dystrophy, Duchenne with a site in United States are open now. Recruiting first, the newest first:
Vanderbilt University Medical Center · Sites in United States
Ages 18+ · Men only
Sarepta Therapeutics, Inc. · Sites in United States
Ages 4+ · Men only
University of Florida · Sites in United States
Ages 6+ · Men only
Vanderbilt University Medical Center · Sites in United States
Ages 8–18 · Men only
University of Rochester · Sites in United States
Ages 0 days–3 yrs · Men only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.
This study: 0 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
233 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 57 · Phase 2 91 · Phase 3 40 · Phase 4 5
First in 2000; this study’s year is marked. 6 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 7 is below the median of 25 across 333 interventional studies indexed under Muscular Dystrophy, Duchenne.
Median enrollment 25 across the 172 interventional studies, 75 across the 55 observational. Of the 161 that completed or were terminated, 78 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
131 of 233 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,338 studies on the registry; 147 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 393 (65%) have results posted.
Pfizer has 9 studies filed under Muscular Dystrophy, Duchenne — fewer than ten, so there is no comparison to draw.
18 of the studies in Muscular Dystrophy, Duchenne with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05881408Phase 3Sarepta Therapeutics, Inc.A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD) | 2027-05-31 |
| NCT06290713University of FloridaVasodilator and Exercise Study for DMD (VASO-REx) | 2026-11 |
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
| NCT05016908Massachusetts General HospitalExtracellular RNA Biomarkers of Duchenne Muscular Dystrophy | 2026-12 |
| NCT00390104Boston Children's HospitalMolecular Analysis of Patients With Neuromuscular Disease | 2026-12-31 |
Add all 18 to your calendar (.ics) → With an account.
Among the 233 studies in Muscular Dystrophy, Duchenne with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to understand the safety and effects of an experimental gene therapy called fordadistrogene movaparvovec. We are seeking participants from previous Pfizer interventional studies. We will follow participants' experience in this study for 10 years after the end of their previous study. Participants will have 1 annual onsite visit and a few annual remote visits. The exact number of remote visits will be decided by their study doctor.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
All participants enrolled in the study.
Biological: fordadistrogene movaparvovec
gene therapy administered in a previous study.
Number of Participants With Treatment Emergent Serious Adverse Events (SAEs)
An SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, was a congenital anomaly or birth defect, other medically significant events and research related injury. All adverse events (AEs) were considered as treatment emergent as follow-up within this study was post-fordadistrogene movaparvovec dosing.
Time frame: From baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study) until end of study (approximately up to 2.5 years)
Number of Participants With Treatment Related Treatment-Emergent Adverse Events (TEAEs)
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of product under study, whether or not considered related to the product under study. AEs included SAEs and all non-SAEs. SAEs were defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, was a congenital anomaly or birth defect, other medically significant events and research related Injury. All AEs were considered as treatment emergent as follow-up within this study was post-fordadistrogene movaparvovec dosing. A treatment-related AE was any untoward medical occurrence attributed to study intervention in a participant who received study intervention. Relatedness to study intervention was assessed by investigator.
Time frame: From baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study) until end of study (approximately up to 2.5 years)
Number of Participants With Clinically Significant Abnormalities in Cardiac Troponin I
Number of participants with clinically significant abnormalities in cardiac troponin I were reported in this outcome measure. Clinical significance of cardiac troponin I abnormalities was determined by the investigator.
Time frame: From baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study) until end of study (approximately up to 2.5 years)
Number of Participants With Clinically Significant Abnormalities in Echocardiogram Parameters
Echocardiogram was performed using a 2-dimensional (2-D) imaging collection method and the parameters evaluated included left ventricular ejection fraction (LVEF). Clinical significance of abnormalities in echocardiogram parameters was determined by the investigator.
Time frame: From baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study) until end of study (approximately up to 2.5 years)
Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG) Parameters
Standard 12-lead ECGs were performed using an ECG machine that automatically calculated the heart rate (HR) and measured PR interval, QT interval, QT interval corrected by Fridericia's formula (QTcF) and QRS complex after the participant had rested quietly for at least 10 minutes in a supine or sitting position. Clinical significance of ECG parameters was determined by the investigator.
Time frame: From baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study) until end of study (approximately up to 2.5 years)
Number of Participants With Malignancy Events
Number of participants with malignancy events as collected on the case report form (CRF) were reported in this outcome measure.
Time frame: From baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study) until end of study (approximately up to 2.5 years)
Number of Participants With Non-Ambulatory Status at Baseline, Year 1 and Year 2
Number of participants with non-ambulatory status at Baseline, Year 1 and Year 2 were reported in this outcome measure. Participants were asked to walk 10 meters unassisted. Participants who were unable to walk 10 meters unassisted were considered as non-ambulatory.
Time frame: Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study), Year 1 and Year 2
Time to Loss of Ambulation
Time to loss of ambulation was defined as the time from pre-fordadistrogene movaparvovec dosing in parent study to loss of participant's ability to walk 10 meters unassisted. Kaplan-Meier method was used.
Time frame: From pre-fordadistrogene movaparvovec dosing in parent study until end of this study (approximately up to 7.5 years)
Number of Participants Who Were Unable to Climb Stairs at Baseline, Year 1 and Year 2
Participants were asked if they were able to climb 1 flight of stairs. Investigator staff entered "Yes" or "No" depending on the participant's response. Number of participants who were unable to climb stairs (i.e., responded as No) at Baseline, Year 1 and Year 2 were reported in this outcome measure.
Time frame: Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study), Year 1 and Year 2
Time to Loss of Ability to Climb Stairs
Time to loss of ability of participant to climb 1 flight of stairs is reported in this outcome measure. Kaplan-Meier method was used.
Time frame: From pre-fordadistrogene movaparvovec dosing in parent study until end of this study (approximately up to 7.5 years)
Change From Pre-Fordadistrogene Movaparvovec Administration in Performance of the Upper Limb (PUL) 2.0 Entry Score at Baseline, Year 1 and Year 2
PUL 2.0 was used to detect progression of the upper limb involvement. The entry item on the PUL 2.0 assessed the use of arms and hands on a scale of 0 (no function) to 6 (full function); higher scores indicated better functioning of arms and hands. Baseline: screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study.
Time frame: Pre-fordadistrogene movaparvovec administration (last non-missing assessment collected prior to dosing of fordadistrogene movaparvovec in parent study); Baseline, Year 1 and Year 2
Change From Baseline in PUL 2.0 Entry Score at Year 1 and Year 2
PUL 2.0 was used to detect progression of the upper limb involvement. The entry item on the PUL 2.0 assessed the use of arms and hands on a scale of 0 (no function) to 6 (full function); higher scores indicated better functioning of arms and hands.
Time frame: Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study); Year 1 and Year 2
Change From Pre-Fordadistrogene Movaparvovec Administration in North Star Ambulatory Assessment (NSAA) Total Score at Baseline, Year 1 and Year 2
The NSAA was a 17-item test that graded performance of various functional skills using the following scale: 0 (unable to achieve independently), 1 (modified method but achieved goal independent of physical assistance from another), and 2 ("normal"- no obvious modification of activity). Total score was calculated as the sum of all 17 individual item responses and ranged from 0 (worst) to 34 (fully independent function) with higher scores indicating better function. Baseline: screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study.
Time frame: Pre-fordadistrogene movaparvovec administration (last non-missing assessment collected prior to dosing of fordadistrogene movaparvovec in parent study); Baseline, Year 1 and Year 2
Change From Baseline in NSAA Total Score at Year 1 and Year 2
The NSAA was a 17-item test that graded performance of various functional skills using the following scale: 0 (unable to achieve independently), 1 (modified method but achieved goal independent of physical assistance from another), and 2 ("normal"- no obvious modification of activity). Total score was calculated as the sum of all 17 individual item responses and ranged from 0 (worst) to 34 (fully independent function) with higher scores indicating better function.
Time frame: Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study); Year 1 and Year 2
Change From Pre-Fordadistrogene Movaparvovec Administration in Percent (%) Predicted Forced Vital Capacity (pFVC) at Baseline, Year 1 and Year 2
Forced vital capacity (FVC) was the volume of air that can be maximally forcefully exhaled after taking the deepest breath possible and was measured using spirometry. The %pFVC was calculated from FVC (measured in liter) according to age, height, race, and gender using multi-ethnic reference values for spirometry. Baseline: screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study.
Time frame: Pre-fordadistrogene movaparvovec administration (last non-missing assessment collected prior to dosing of fordadistrogene movaparvovec in parent study); Baseline, Year 1 and Year 2
Change From Baseline in %pFVC at Year 1 and Year 2
FVC was the volume of air that can be maximally forcefully exhaled after taking the deepest breath possible and was measured using spirometry. The %pFVC was calculated from FVC (measured in liter) according to age, height, race, and gender using multi-ethnic reference values for spirometry.
Time frame: Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study); Year 1 and Year 2
Change From Pre-Fordadistrogene Movaparvovec Administration in %Predicted Peak Expiratory Flow (pPEF) at Baseline, Year 1 and Year 2
PEF was the maximum speed of expiration measured using spirometer. The %pPEF was calculated from PEF according to age, height, race, and gender using multi-ethnic reference values for spirometry. Baseline: screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study.
Time frame: Pre-fordadistrogene movaparvovec administration (last non-missing assessment collected prior to dosing of fordadistrogene movaparvovec in parent study); Baseline, Year 1 and Year 2
Change From Baseline in %pPEF at Year 1 and Year 2
PEF was the maximum speed of expiration measured using spirometer. The %pPEF was calculated from PEF according to age, height, race, and gender using multi-ethnic reference values for spirometry.
Time frame: Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study); Year 1 and Year 2
Change From Pre-Fordadistrogene Movaparvovec Administration in LVEF at Baseline, Year 1 and Year 2
LVEF was evaluated using the echocardiogram. Change from pre-fordadistrogene movaparvovec administration in LVEF at Baseline, Year 1 and Year 2 was reported in this outcome measure. Baseline: screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study.
Time frame: Pre-fordadistrogene movaparvovec administration (last non-missing assessment collected prior to dosing of fordadistrogene movaparvovec in parent study); Baseline, Year 1 and Year 2
Change From Baseline in LVEF at Year 1 and Year 2
LVEF was evaluated using the echocardiogram. Change from Baseline in LVEF at Year 1 and Year 2 was reported in this outcome measure.
Time frame: Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study); Year 1 and Year 2
Age of Participants When %pFVC is <30%
FVC was the volume of air that can be maximally forcefully exhaled after taking the deepest breath possible and was measured using spirometry. The %pFVC was calculated from FVC (measured in liter) according to age, height, race, and gender using multi-ethnic reference values for spirometry.
Time frame: From Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study) until end of study (approximately up to 2.5 years)
Age of Participants at Loss of Ambulation
Loss of ambulation was defined as the loss of participant's ability to walk 10 meters unassisted. Age of participants at loss of ambulation is reported in this outcome measure.
Time frame: From Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study) until end of study (approximately up to 2.5 years)
Age of Participants at the Time of Death
Time frame: From Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study) until end of study (approximately up to 2.5 years)
Number of Participants According to Cause of Death
Time frame: From Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study) until end of study (approximately up to 2.5 years)
Change From Pre-Fordadistrogene Movaparvovec Administration in Glucocorticoid Dose at Baseline, Year 1 and Year 2
Change from pre-fordadistrogene movaparvovec administration in dose of glucocorticoids including prednisone/ prednisolone, and deflazacort at Baseline, Year 1 and Year 2 was reported in this outcome measure. Baseline: screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study.
Time frame: Pre-fordadistrogene movaparvovec administration (last non-missing assessment collected prior to dosing of fordadistrogene movaparvovec in parent study); Baseline, Year 1 and Year 2
Change From Pre-Fordadistrogene Movaparvovec Administration in Modified Pediatric Outcomes Data Collection Instrument (PODCI) Transfer and Basic Mobility Core Scale at Baseline, Year 1 and Year 2: Proxy Report (Parent Version)
Modified PODCI pediatric parent version was completed by caregivers of all participants. Modified PODCI - Pediatric Parent version comprised of a total of 32 items under 2 scales: Transfer and Basic Mobility Core Scale (11 items) and Sports and Physical Functioning Core Scale (21 items). The transfer and basic mobility scale assessed how caregivers of participants evaluated a participant's ability to walk, stand, and perform activities of daily living. The scale produced an independent, standardized score ranging from 0 (low function) to 100 (high function), with lower scores representing lower levels of function. Baseline: screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study.
Time frame: Pre-fordadistrogene movaparvovec administration (last non-missing assessment collected prior to dosing of fordadistrogene movaparvovec in parent study); Baseline, Year 1 and Year 2
Change From Pre-Fordadistrogene Movaparvovec Administration in Modified PODCI Transfer and Basic Mobility Core Scale at Baseline, Year 1 and Year 2: Self Report (Adolescent Version)
Modified PODCI adolescent version was completed by participants \>=11 years of age. Modified PODCI - Adolescent version comprised of a total of 29 items under 2 scales: Transfer and Basic Mobility Core Scale (11 items) and Sports and Physical Functioning Core Scale (18 items). The transfer and basic mobility scale assessed how participants evaluated their ability to walk, stand, and perform activities of daily living. The scale produced an independent, standardized score ranging from 0 (low function) to 100 (high function), with lower scores representing lower levels of function. Baseline: screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study.
Time frame: Pre-fordadistrogene movaparvovec administration (last non-missing assessment collected prior to dosing of fordadistrogene movaparvovec in parent study); Baseline, Year 1 and Year 2
Change From Baseline in Modified PODCI Transfer and Basic Mobility Core Scale at Year 1 and Year 2: Proxy Report (Parent Version)
Modified PODCI pediatric parent version was completed by caregivers of all participants. Modified PODCI - Pediatric Parent version comprised of a total of 32 items under 2 scales: Transfer and Basic Mobility Core Scale (11 items) and Sports and Physical Functioning Core Scale (21 items). The transfer and basic mobility scale assessed how caregivers of participants evaluated a participant's ability to walk, stand, and perform activities of daily living. The scale produced an independent, standardized score ranging from 0 (low function) to 100 (high function), with lower scores representing lower levels of function.
Time frame: Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study); Year 1 and Year 2
Change From Baseline in Modified PODCI Transfer and Basic Mobility Core Scale at Year 1 and Year 2: Self Report (Adolescent Version)
Modified PODCI adolescent version was completed by participants \>=11 years of age. Modified PODCI - Adolescent version comprised of a total of 29 items under 2 scales: Transfer and Basic Mobility Core Scale (11 items) and Sports and Physical Functioning Core Scale (18 items). The transfer and basic mobility scale assessed how participants evaluated their ability to walk, stand, and perform activities of daily living. The scale produced an independent, standardized score ranging from 0 (low function) to 100 (high function), with lower scores representing lower levels of function.
Time frame: Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study); Year 1 and Year 2
Change From Pre-Fordadistrogene Movaparvovec Administration in Modified PODCI Sports and Physical Functioning Core Scale at Baseline, Year 1 and Year 2: Proxy Report (Parent Version)
Modified PODCI pediatric parent version was completed by caregivers of all participants. Modified PODCI - Pediatric Parent version comprised of a total of 32 items under 2 scales: Transfer and Basic Mobility Core Scale (11 items) and Sports and Physical Functioning Core Scale (21 items). The sports and physical functioning core scale assessed how caregivers of participants evaluated a participant's ability to perform recreational activities. The scale produced an independent, standardized score ranging from 0 (low function) to 100 (high function), with lower scores representing lower levels of function. Baseline: screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study.
Time frame: Pre-fordadistrogene movaparvovec administration (last non-missing assessment collected prior to dosing of fordadistrogene movaparvovec in parent study); Baseline, Year 1 and Year 2
Change From Pre-Fordadistrogene Movaparvovec Administration in Modified PODCI Sports and Physical Functioning Core Scale at Baseline, Year 1 and Year 2: Self Report (Adolescent Version)
Modified PODCI adolescent version was completed by participants \>=11 years of age. Modified PODCI - Adolescent version comprised of a total of 29 items under 2 scales: Transfer and Basic Mobility Core Scale (11 items) and Sports and Physical Functioning Core Scale (18 items). The sports and physical functioning core scale assessed how participants evaluated their ability to perform recreational activities. The scale produced an independent, standardized score ranging from 0 (low function) to 100 (high function), with lower scores representing lower levels of function. Baseline: screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study.
Time frame: Pre-fordadistrogene movaparvovec administration (last non-missing assessment collected prior to dosing of fordadistrogene movaparvovec in parent study); Baseline, Year 1 and Year 2
Change From Baseline in Modified PODCI Sports and Physical Functioning Core Scale at Year 1 and Year 2: Proxy Report (Parent Version)
Modified PODCI pediatric parent version was completed by caregivers of all participants. Modified PODCI - Pediatric Parent version comprised of a total of 32 items under 2 scales: Transfer and Basic Mobility Core Scale (11 items) and Sports and Physical Functioning Core Scale (21 items). The sports and physical functioning core scale assessed how caregivers of participants evaluated a participant's ability to perform recreational activities. The scale produced an independent, standardized score ranging from 0 (low function) to 100 (high function), with lower scores representing lower levels of function.
Time frame: Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study); Year 1 and Year 2
Change From Baseline in Modified PODCI Sports and Physical Functioning Core Scale at Year 1 and Year 2: Self Report (Adolescent Version)
Modified PODCI adolescent version was completed by participants \>=11 years of age. Modified PODCI - Adolescent version comprised of a total of 29 items under 2 scales: Transfer and Basic Mobility Core Scale (11 items) and Sports and Physical Functioning Core Scale (18 items). The sports and physical functioning core scale assessed how participants evaluated their ability to perform recreational activities. The scale produced an independent, standardized score ranging from 0 (low function) to 100 (high function), with lower scores representing lower levels of function.
Time frame: Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study); Year 1 and Year 2
Change From Pre-Fordadistrogene Movaparvovec Administration in Upper Limb Function Patient Reported Outcome Measure (UL-PROM) at Baseline, Year 1 and Year 2
The UL-PROM was developed based on Food and Drug Administration (FDA) guidelines to assess activities of daily living in DMD participants that could not be observed in a clinical setting. The 32-item questionnaire covered 4 domains: food, self-care, household and environment, and leisure and communication. There were 3 possible response options for each item: 2 =can do easily, 1=can do with difficulty, and 0=impossible without help. The UL-PROM total score was calculated as the sum of the individual item responses and ranged from 0 to 64, with higher scores indicating better function. The total score was standardized to a score range of 0 (low function) to 100 (high function) by multiplying by 100 and dividing by 64, where higher scores indicated better function. The UL-PROM had to be completed only by non-ambulatory participants as pre-specified in the protocol. Baseline: screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study.
Time frame: Pre-fordadistrogene movaparvovec administration (last non-missing assessment collected prior to dosing of fordadistrogene movaparvovec in parent study); Baseline, Year 1 and Year 2
A total of 7 participants were enrolled in this long-term follow-up study. The study was terminated to streamline the long term follow up for all participants after the development of fordadistrogene movaparvovec was discontinued due to lack of efficacy in the pivotal Phase 3 study C3391003 \[NCT04281485\].
| Milestone | All Participants |
|---|---|
| Started | 7 |
| Completed | 0 |
| Not completed | 7 |
| Withdrew: Study terminated by sponsor | 6 |
| Withdrew: Withdrawal by subject | 1 |
An SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, was a congenital anomaly or birth defect, other medically significant events and research related injury. All adverse events (AEs) were considered as treatment emergent as follow-up within this study was post-fordadistrogene movaparvovec dosing.
| Participants | All Participants |
|---|---|
| Number of Participants With Treatment Emergent Serious Adverse Events (SAEs) | 3 |
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of product under study, whether or not considered related to the product under study. AEs included SAEs and all non-SAEs. SAEs were defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, was a congenital anomaly or birth defect, other medically significant events and research related Injury. All AEs were considered as treatment emergent as follow-up within this study was post-fordadistrogene movaparvovec dosing. A treatment-related AE was any untoward medical occurrence attributed to study intervention in a participant who received study intervention. Relatedness to study intervention was assessed by investigator.
| Participants | All Participants |
|---|---|
| Number of Participants With Treatment Related Treatment-Emergent Adverse Events (TEAEs) | 0 |
Number of participants with clinically significant abnormalities in cardiac troponin I were reported in this outcome measure. Clinical significance of cardiac troponin I abnormalities was determined by the investigator.
| Participants | All Participants |
|---|---|
| Number of Participants With Clinically Significant Abnormalities in Cardiac Troponin I | 0 |
Echocardiogram was performed using a 2-dimensional (2-D) imaging collection method and the parameters evaluated included left ventricular ejection fraction (LVEF). Clinical significance of abnormalities in echocardiogram parameters was determined by the investigator.
| Participants | All Participants |
|---|---|
| Number of Participants With Clinically Significant Abnormalities in Echocardiogram Parameters | 0 |
Standard 12-lead ECGs were performed using an ECG machine that automatically calculated the heart rate (HR) and measured PR interval, QT interval, QT interval corrected by Fridericia's formula (QTcF) and QRS complex after the participant had rested quietly for at least 10 minutes in a supine or sitting position. Clinical significance of ECG parameters was determined by the investigator.
| Participants | All Participants |
|---|---|
| Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG) Parameters | 0 |
Number of participants with malignancy events as collected on the case report form (CRF) were reported in this outcome measure.
| Participants | All Participants |
|---|---|
| Number of Participants With Malignancy Events | 0 |
Number of participants with non-ambulatory status at Baseline, Year 1 and Year 2 were reported in this outcome measure. Participants were asked to walk 10 meters unassisted. Participants who were unable to walk 10 meters unassisted were considered as non-ambulatory.
| Participants | All Participants |
|---|---|
| Baseline | 3 |
| Year 1 | 2 |
| Year 2 | 0 |
Time to loss of ambulation was defined as the time from pre-fordadistrogene movaparvovec dosing in parent study to loss of participant's ability to walk 10 meters unassisted. Kaplan-Meier method was used.
| Years | All Participants |
|---|---|
| Time to Loss of Ambulation | NA (3.91 to NA) |
Participants were asked if they were able to climb 1 flight of stairs. Investigator staff entered "Yes" or "No" depending on the participant's response. Number of participants who were unable to climb stairs (i.e., responded as No) at Baseline, Year 1 and Year 2 were reported in this outcome measure.
| Participants | All Participants |
|---|---|
| Baseline | 4 |
| Year 1 | 2 |
| Year 2 | 1 |
Time to loss of ability of participant to climb 1 flight of stairs is reported in this outcome measure. Kaplan-Meier method was used.
| Years | All Participants |
|---|---|
| Time to Loss of Ability to Climb Stairs | 4.97 (3.04 to NA) |
PUL 2.0 was used to detect progression of the upper limb involvement. The entry item on the PUL 2.0 assessed the use of arms and hands on a scale of 0 (no function) to 6 (full function); higher scores indicated better functioning of arms and hands. Baseline: screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study.
| Units on a scale | All Participants |
|---|---|
| Baseline | -0.8 ± 1.17 |
| Year 1 | -0.8 ± 1.5 |
| Year 2 | 0.0 ± 0.0 |
PUL 2.0 was used to detect progression of the upper limb involvement. The entry item on the PUL 2.0 assessed the use of arms and hands on a scale of 0 (no function) to 6 (full function); higher scores indicated better functioning of arms and hands.
| Units on a scale | All Participants |
|---|---|
| Year 1 | 0.3 ± 0.5 |
| Year 2 | 0.0 ± 0.0 |
The NSAA was a 17-item test that graded performance of various functional skills using the following scale: 0 (unable to achieve independently), 1 (modified method but achieved goal independent of physical assistance from another), and 2 ("normal"- no obvious modification of activity). Total score was calculated as the sum of all 17 individual item responses and ranged from 0 (worst) to 34 (fully independent function) with higher scores indicating better function. Baseline: screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study.
| Units on a scale | All Participants |
|---|---|
| Baseline | -12.3 ± 11.7 |
| Year 1 | -14.5 ± 4.95 |
| Year 2 | -14.0 ± 7.07 |
The NSAA was a 17-item test that graded performance of various functional skills using the following scale: 0 (unable to achieve independently), 1 (modified method but achieved goal independent of physical assistance from another), and 2 ("normal"- no obvious modification of activity). Total score was calculated as the sum of all 17 individual item responses and ranged from 0 (worst) to 34 (fully independent function) with higher scores indicating better function.
| Units on a scale | All Participants |
|---|---|
| Year 1 | -6.0 ± 5.66 |
| Year 2 | -5.5 ± 3.54 |
Forced vital capacity (FVC) was the volume of air that can be maximally forcefully exhaled after taking the deepest breath possible and was measured using spirometry. The %pFVC was calculated from FVC (measured in liter) according to age, height, race, and gender using multi-ethnic reference values for spirometry. Baseline: screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study.
| Percentage of pFVC | All Participants |
|---|---|
| Baseline | -15.57 ± 25.973 |
| Year 1 | -19.5 ± 28.314 |
| Year 2 | -21.5 ± 31.82 |
FVC was the volume of air that can be maximally forcefully exhaled after taking the deepest breath possible and was measured using spirometry. The %pFVC was calculated from FVC (measured in liter) according to age, height, race, and gender using multi-ethnic reference values for spirometry.
| Percentage of pFVC | All Participants |
|---|---|
| Year 1 | -7.25 ± 7.136 |
| Year 2 | -4.0 ± 12.728 |
PEF was the maximum speed of expiration measured using spirometer. The %pPEF was calculated from PEF according to age, height, race, and gender using multi-ethnic reference values for spirometry. Baseline: screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study.
No measurements were reported for this outcome.
PEF was the maximum speed of expiration measured using spirometer. The %pPEF was calculated from PEF according to age, height, race, and gender using multi-ethnic reference values for spirometry.
| Percentage of pPEF | All Participants |
|---|---|
| Year 1 | -3.02 ± 12.584 |
| Year 2 | 14.95 ± 17.324 |
LVEF was evaluated using the echocardiogram. Change from pre-fordadistrogene movaparvovec administration in LVEF at Baseline, Year 1 and Year 2 was reported in this outcome measure. Baseline: screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study.
| Percentage of ejected blood | All Participants |
|---|---|
| Baseline | -4.0 ± NA |
LVEF was evaluated using the echocardiogram. Change from Baseline in LVEF at Year 1 and Year 2 was reported in this outcome measure.
| Percentage of ejected blood | All Participants |
|---|---|
| Year 1 | -1.0 ± 2.0 |
| Year 2 | -16.0 ± NA |
FVC was the volume of air that can be maximally forcefully exhaled after taking the deepest breath possible and was measured using spirometry. The %pFVC was calculated from FVC (measured in liter) according to age, height, race, and gender using multi-ethnic reference values for spirometry.
No measurements were reported for this outcome.
Loss of ambulation was defined as the loss of participant's ability to walk 10 meters unassisted. Age of participants at loss of ambulation is reported in this outcome measure.
| Years | All Participants |
|---|---|
| Age of Participants at Loss of Ambulation | 14.3 ± 1.53 |
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Change from pre-fordadistrogene movaparvovec administration in dose of glucocorticoids including prednisone/ prednisolone, and deflazacort at Baseline, Year 1 and Year 2 was reported in this outcome measure. Baseline: screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study.
| Milligrams per kilogram per day | All Participants |
|---|---|
| Baseline: Prednisone/ Prednisolone | -0.06 ± 0.0966 |
| Year 1: Prednisone/ Prednisolone | -0.161 ± NA |
| Baseline: Deflazacort | -0.194 ± 0.3467 |
| Year 1: Deflazacort | 0.079 ± 0.2057 |
| Year 2: Deflazacort | -0.022 ± NA |
Modified PODCI pediatric parent version was completed by caregivers of all participants. Modified PODCI - Pediatric Parent version comprised of a total of 32 items under 2 scales: Transfer and Basic Mobility Core Scale (11 items) and Sports and Physical Functioning Core Scale (21 items). The transfer and basic mobility scale assessed how caregivers of participants evaluated a participant's ability to walk, stand, and perform activities of daily living. The scale produced an independent, standardized score ranging from 0 (low function) to 100 (high function), with lower scores representing lower levels of function. Baseline: screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study.
| Units on a scale | All Participants |
|---|---|
| Baseline | -31.78 ± 24.5405 |
| Year 1 | -35.101 ± 20.7793 |
| Year 2 | -46.97 ± 26.7843 |
Modified PODCI adolescent version was completed by participants \>=11 years of age. Modified PODCI - Adolescent version comprised of a total of 29 items under 2 scales: Transfer and Basic Mobility Core Scale (11 items) and Sports and Physical Functioning Core Scale (18 items). The transfer and basic mobility scale assessed how participants evaluated their ability to walk, stand, and perform activities of daily living. The scale produced an independent, standardized score ranging from 0 (low function) to 100 (high function), with lower scores representing lower levels of function. Baseline: screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study.
| Units on a scale | All Participants |
|---|---|
| Baseline | -71.212 ± NA |
| Year 1 | -64.394 ± NA |
Modified PODCI pediatric parent version was completed by caregivers of all participants. Modified PODCI - Pediatric Parent version comprised of a total of 32 items under 2 scales: Transfer and Basic Mobility Core Scale (11 items) and Sports and Physical Functioning Core Scale (21 items). The transfer and basic mobility scale assessed how caregivers of participants evaluated a participant's ability to walk, stand, and perform activities of daily living. The scale produced an independent, standardized score ranging from 0 (low function) to 100 (high function), with lower scores representing lower levels of function.
| Units on a scale | All Participants |
|---|---|
| Year 1 | -9.596 ± 5.0442 |
| Year 2 | -30.682 ± 24.1059 |
Modified PODCI adolescent version was completed by participants \>=11 years of age. Modified PODCI - Adolescent version comprised of a total of 29 items under 2 scales: Transfer and Basic Mobility Core Scale (11 items) and Sports and Physical Functioning Core Scale (18 items). The transfer and basic mobility scale assessed how participants evaluated their ability to walk, stand, and perform activities of daily living. The scale produced an independent, standardized score ranging from 0 (low function) to 100 (high function), with lower scores representing lower levels of function.
| Units on a scale | All Participants |
|---|---|
| Year 1 | -12.879 ± 25.5113 |
| Year 2 | -9.091 ± 2.1427 |
Modified PODCI pediatric parent version was completed by caregivers of all participants. Modified PODCI - Pediatric Parent version comprised of a total of 32 items under 2 scales: Transfer and Basic Mobility Core Scale (11 items) and Sports and Physical Functioning Core Scale (21 items). The sports and physical functioning core scale assessed how caregivers of participants evaluated a participant's ability to perform recreational activities. The scale produced an independent, standardized score ranging from 0 (low function) to 100 (high function), with lower scores representing lower levels of function. Baseline: screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study.
| Units on a scale | All Participants |
|---|---|
| Baseline | -38.426 ± 23.1643 |
| Year 1 | -28.914 ± 26.6057 |
| Year 2 | -22.506 ± 28.3468 |
Modified PODCI adolescent version was completed by participants \>=11 years of age. Modified PODCI - Adolescent version comprised of a total of 29 items under 2 scales: Transfer and Basic Mobility Core Scale (11 items) and Sports and Physical Functioning Core Scale (18 items). The sports and physical functioning core scale assessed how participants evaluated their ability to perform recreational activities. The scale produced an independent, standardized score ranging from 0 (low function) to 100 (high function), with lower scores representing lower levels of function. Baseline: screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study.
| Units on a scale | All Participants |
|---|---|
| Baseline | -51.288 ± NA |
| Year 1 | -44.697 ± NA |
Modified PODCI pediatric parent version was completed by caregivers of all participants. Modified PODCI - Pediatric Parent version comprised of a total of 32 items under 2 scales: Transfer and Basic Mobility Core Scale (11 items) and Sports and Physical Functioning Core Scale (21 items). The sports and physical functioning core scale assessed how caregivers of participants evaluated a participant's ability to perform recreational activities. The scale produced an independent, standardized score ranging from 0 (low function) to 100 (high function), with lower scores representing lower levels of function.
| Units on a scale | All Participants |
|---|---|
| Year 1 | 0.189 ± 9.5531 |
| Year 2 | -8.617 ± 13.6154 |
Modified PODCI adolescent version was completed by participants \>=11 years of age. Modified PODCI - Adolescent version comprised of a total of 29 items under 2 scales: Transfer and Basic Mobility Core Scale (11 items) and Sports and Physical Functioning Core Scale (18 items). The sports and physical functioning core scale assessed how participants evaluated their ability to perform recreational activities. The scale produced an independent, standardized score ranging from 0 (low function) to 100 (high function), with lower scores representing lower levels of function.
| Units on a scale | All Participants |
|---|---|
| Year 1 | -12.986 ± 6.58 |
| Year 2 | -22.506 ± 3.0802 |
The UL-PROM was developed based on Food and Drug Administration (FDA) guidelines to assess activities of daily living in DMD participants that could not be observed in a clinical setting. The 32-item questionnaire covered 4 domains: food, self-care, household and environment, and leisure and communication. There were 3 possible response options for each item: 2 =can do easily, 1=can do with difficulty, and 0=impossible without help. The UL-PROM total score was calculated as the sum of the individual item responses and ranged from 0 to 64, with higher scores indicating better function. The total score was standardized to a score range of 0 (low function) to 100 (high function) by multiplying by 100 and dividing by 64, where higher scores indicated better function. The UL-PROM had to be completed only by non-ambulatory participants as pre-specified in the protocol. Baseline: screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study.
No measurements were reported for this outcome.
Collected over From Baseline (screening visit within this study, approximately 5 years post fordadistrogene movaparvovec dose in parent study) until end of study (approximately up to 2.5 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| All Participants | 0/7 (0%) | 3/7 (42.9%) | 4/7 (57.1%) |
| Event | All Participants |
|---|---|
| Cardiac failure congestiveCardiac disorders | 1/7 |
| FallInjury, poisoning and procedural complications | 1/7 |
| Femur fractureInjury, poisoning and procedural complications | 1/7 |
| SchwannomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/7 |
| Event | All Participants |
|---|---|
| InfluenzaInfections and infestations | 1/7 |
| FallInjury, poisoning and procedural complications | 1/7 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 1/7 |
| HypotensionVascular disorders | 1/7 |
| Age, Continuous(Years) | All Participants |
|---|---|
| Mean | 13.4 ± 1.81 |
| Sex: Female, Male(Participants) | All Participants |
|---|---|
| Female | 0 |
| Male | 7 |
| Ethnicity (NIH/OMB)(Participants) | All Participants |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 6 |
| Unknown or Not Reported | 1 |
| Race (NIH/OMB)(Participants) | All Participants |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 7 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Mar 2023 to primary completion in Sep 2025, 30 months.
Results were first posted in Nov 2026, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Muscular Dystrophy, Duchenne →